

46 Pre  
3-27-02  
P. 2.

**PATENT**  
Attorney Docket No. 213187

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Kovesdi et al.

Art Unit: Unassigned

Continuation of U.S. Patent  
Application No. 08/258,416

Examiner: Unassigned

Filed: August 21, 2001

For: ADENOVECTOR PHARMACEUTICAL  
COMPOSITION

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments and consider the following remarks.

**AMENDMENTS**

**IN THE TITLE:**

Replace the title with:

ADENOVECTOR PHARMACEUTICAL COMPOSITION

**IN THE SPECIFICATION:**

At page 1, line 1, insert:

This patent application is a continuation of copending U.S. Patent  
Application No. 08/258,416, filed June 10, 1994.

**IN THE CLAIMS:**

Please cancel claims 1-35 and add the following claims:

36. (New) A pharmaceutical composition comprising recombinant adenoviral vectors and a pharmaceutically acceptable carrier, wherein each recombinant adenoviral vector is deficient in one or more essential gene functions of one or more regions of the adenoviral genome selected from the group consisting of the E1, E2A, and E4 regions of the